Please assess the completion status of the following clinical trial:

Trial Title: Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with locally invasive or metastatic, epithelial ovarian, fallopian tube, or primary peritoneal cancer~* Subjects must provide samples of tumor tissue~* Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Exclusion Criteria:~* Subjects with low-grade ovarian, fallopian tube, or Primary peritoneal cancer~* Women who are pregnant or breast feeding~* Subjects who have an active hepatitis B virus or hepatitis C virus infection requiring treatment as defined in the protocol

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anetumab ravtansine (Type: EXPERIMENTAL): Anetumab ravtansine in combination with pegylated liposomal doxorubicin in subjects with mesothelin-expressing platinum-resistant recurrent ovarian, fallopian tube, or primary peritoneal cancer. Increase/Decrease of Anetumab ravtansine until maximum tolerated dose identified.

Based on this trial design, predict the completion outcome and termination type (if applicable).